NGL Fine-Chem Limited (NSE:NGLFINE)
India · Delayed Price · Currency is INR 1,222.30
-38.30 (-3.04%)
Aug 6, 2025, 3:29 PM IST
Verve Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 3,817 | 3,683 | 3,387 | 2,781 | 3,175 | 2,580 | Upgrade |
Other Revenue | -0 | -0 | - | - | - | - | Upgrade |
| 3,817 | 3,683 | 3,387 | 2,781 | 3,175 | 2,580 | Upgrade | |
Revenue Growth (YoY) | 6.50% | 8.73% | 21.80% | -12.42% | 23.08% | 70.07% | Upgrade |
Cost of Revenue | 1,989 | 1,942 | 1,691 | 1,489 | 1,554 | 1,089 | Upgrade |
Gross Profit | 1,828 | 1,741 | 1,696 | 1,292 | 1,621 | 1,491 | Upgrade |
Selling, General & Admin | 615.09 | 576.65 | 479.76 | 391.78 | 365.99 | 302.76 | Upgrade |
Other Operating Expenses | 858 | 825.56 | 683.63 | 556.64 | 576.24 | 344.86 | Upgrade |
Operating Expenses | 1,610 | 1,527 | 1,280 | 1,061 | 1,046 | 730.96 | Upgrade |
Operating Income | 217.8 | 214.18 | 416.27 | 230.29 | 574.76 | 759.62 | Upgrade |
Interest Expense | -31.13 | -23.34 | -13.38 | -11.97 | -15.62 | -18.4 | Upgrade |
Interest & Investment Income | 8.3 | 8.3 | 10.63 | 8.73 | 5.43 | 2.02 | Upgrade |
Currency Exchange Gain (Loss) | 28.13 | 28.13 | 34.98 | 27.63 | 44.22 | 14.58 | Upgrade |
Other Non Operating Income (Expenses) | 48.61 | 43.92 | 22.47 | 18.94 | 57.18 | 12.53 | Upgrade |
EBT Excluding Unusual Items | 271.72 | 271.19 | 470.97 | 273.62 | 665.96 | 770.35 | Upgrade |
Gain (Loss) on Sale of Investments | 5.95 | 5.95 | 73.2 | - | - | 51.05 | Upgrade |
Other Unusual Items | - | - | - | - | - | -45.5 | Upgrade |
Pretax Income | 277.67 | 277.14 | 544.17 | 273.62 | 665.96 | 775.9 | Upgrade |
Income Tax Expense | 66.21 | 65.9 | 131 | 68.66 | 166.99 | 208.71 | Upgrade |
Net Income | 211.46 | 211.24 | 413.17 | 204.96 | 498.97 | 567.19 | Upgrade |
Net Income to Common | 211.46 | 211.24 | 413.17 | 204.96 | 498.97 | 567.19 | Upgrade |
Net Income Growth | -49.69% | -48.87% | 101.58% | -58.92% | -12.03% | 580.47% | Upgrade |
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 | 6 | Upgrade |
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 | 6 | Upgrade |
EPS (Basic) | 34.23 | 34.19 | 66.88 | 33.18 | 80.77 | 91.81 | Upgrade |
EPS (Diluted) | 34.23 | 34.19 | 66.88 | 33.18 | 80.77 | 91.81 | Upgrade |
EPS Growth | -49.69% | -48.88% | 101.58% | -58.92% | -12.03% | 580.56% | Upgrade |
Free Cash Flow | - | -949.49 | -80.59 | 38.8 | -425.52 | 101.42 | Upgrade |
Free Cash Flow Per Share | - | -153.69 | -13.04 | 6.28 | -68.88 | 16.42 | Upgrade |
Dividend Per Share | - | 1.750 | 1.750 | 1.750 | 1.750 | 1.750 | Upgrade |
Gross Margin | 47.89% | 47.27% | 50.08% | 46.45% | 51.04% | 57.78% | Upgrade |
Operating Margin | 5.71% | 5.82% | 12.29% | 8.28% | 18.10% | 29.45% | Upgrade |
Profit Margin | 5.54% | 5.74% | 12.20% | 7.37% | 15.72% | 21.99% | Upgrade |
Free Cash Flow Margin | - | -25.78% | -2.38% | 1.40% | -13.40% | 3.93% | Upgrade |
EBITDA | 343 | 337.43 | 531.72 | 341.65 | 676.84 | 841.81 | Upgrade |
EBITDA Margin | 8.99% | 9.16% | 15.70% | 12.29% | 21.32% | 32.63% | Upgrade |
D&A For EBITDA | 125.2 | 123.25 | 115.45 | 111.36 | 102.09 | 82.19 | Upgrade |
EBIT | 217.8 | 214.18 | 416.27 | 230.29 | 574.76 | 759.62 | Upgrade |
EBIT Margin | 5.71% | 5.82% | 12.29% | 8.28% | 18.10% | 29.45% | Upgrade |
Effective Tax Rate | 23.84% | 23.78% | 24.07% | 25.09% | 25.07% | 26.90% | Upgrade |
Revenue as Reported | 3,908 | 3,769 | 3,528 | 2,836 | 3,282 | 2,660 | Upgrade |
Advertising Expenses | - | 6.16 | 10.54 | 6.86 | 2.69 | 9.36 | Upgrade |
Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.